Neuralink’s secondary-market valuations have climbed sharply to the $29–42 billion range as of September 2026, driven by robust investor demand for shares amid ongoing clinical trial expansion and demonstrated patient functionality in controlling digital devices. The company’s last primary round closed at roughly $9 billion post-money in mid-2025, while recent secondary transactions reflect a near fivefold increase fueled by 21 trial participants worldwide, including the first Canadian ALS implant in May, and continued FDA Breakthrough designations. With resolution set for December 31, near-term catalysts center on additional enrollment updates, regulatory milestones, or any new primary financing that could sustain or accelerate pricing momentum before year-end. Trader consensus prices these probabilities according to skin-in-the-game capital allocation across private-market platforms.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้วNPM Prices are published for trading days only and are updated once daily at 1:00 PM ET on the following calendar day.
If NPM has not published relevant data for all business dates in the specified period by 1:00 PM ET on January 1, 2027, this market may remain open until 11:59 PM ET on January 4, 2027. If no further data is released by that time, the market will resolve according to the data available.
If NPM ceases publishing relevant data prior to the end of the specified period, this market will resolve based on the NPM data published for the period prior to the cessation of coverage, as well as any applicable public market capitalization data following an IPO or direct listing.
If the company completes an IPO or direct listing before the end of the specified period, this market will consider, in addition to the relevant NPM valuations published between market creation and the IPO or direct listing date, the valuation implied by the official IPO or direct listing price, and the company's public market capitalization between the IPO or direct listing date and the end of the specified period.
Public market capitalization will be determined using the highest/lowest official regular-hours trading price published for the company's primary listed common equity on its primary exchange for any trading day during the specified period, multiplied by the company's total outstanding common shares at the relevant time.
If the listed company merges with or acquires another entity and remains the parent company, no change to resolution methodology applies.
If the listed company is acquired, merges into another entity and is no longer the surviving parent company, or otherwise ceases to exist as an independent entity prior to the end of the period, only NPM valuations and applicable public market capitalizations achieved prior to completion of the transaction will be considered for resolution. No transaction, acquisition, or merger consideration will be considered for resolution.
The resolution source for this market is NPM data published here (https://fe.secondmarket.com/companies/company-782c0a32-4727-4097-a40b-9a2602f243e7/data). The resolution source for any period following an IPO, direct listing, or relevant corporate action, will be official exchange trading data and publicly reported share counts.
Revisions to previously published NPM data made after their initial release will not be considered, unless made to correct clearly erroneous data.
ตลาดเปิดเมื่อ: May 19, 2026, 1:02 AM ET
ผู้ตัดสินผล
0x65070BE91...NPM Prices are published for trading days only and are updated once daily at 1:00 PM ET on the following calendar day.
If NPM has not published relevant data for all business dates in the specified period by 1:00 PM ET on January 1, 2027, this market may remain open until 11:59 PM ET on January 4, 2027. If no further data is released by that time, the market will resolve according to the data available.
If NPM ceases publishing relevant data prior to the end of the specified period, this market will resolve based on the NPM data published for the period prior to the cessation of coverage, as well as any applicable public market capitalization data following an IPO or direct listing.
If the company completes an IPO or direct listing before the end of the specified period, this market will consider, in addition to the relevant NPM valuations published between market creation and the IPO or direct listing date, the valuation implied by the official IPO or direct listing price, and the company's public market capitalization between the IPO or direct listing date and the end of the specified period.
Public market capitalization will be determined using the highest/lowest official regular-hours trading price published for the company's primary listed common equity on its primary exchange for any trading day during the specified period, multiplied by the company's total outstanding common shares at the relevant time.
If the listed company merges with or acquires another entity and remains the parent company, no change to resolution methodology applies.
If the listed company is acquired, merges into another entity and is no longer the surviving parent company, or otherwise ceases to exist as an independent entity prior to the end of the period, only NPM valuations and applicable public market capitalizations achieved prior to completion of the transaction will be considered for resolution. No transaction, acquisition, or merger consideration will be considered for resolution.
The resolution source for this market is NPM data published here (https://fe.secondmarket.com/companies/company-782c0a32-4727-4097-a40b-9a2602f243e7/data). The resolution source for any period following an IPO, direct listing, or relevant corporate action, will be official exchange trading data and publicly reported share counts.
Revisions to previously published NPM data made after their initial release will not be considered, unless made to correct clearly erroneous data.
ผู้ตัดสินผล
0x65070BE91...Neuralink’s secondary-market valuations have climbed sharply to the $29–42 billion range as of September 2026, driven by robust investor demand for shares amid ongoing clinical trial expansion and demonstrated patient functionality in controlling digital devices. The company’s last primary round closed at roughly $9 billion post-money in mid-2025, while recent secondary transactions reflect a near fivefold increase fueled by 21 trial participants worldwide, including the first Canadian ALS implant in May, and continued FDA Breakthrough designations. With resolution set for December 31, near-term catalysts center on additional enrollment updates, regulatory milestones, or any new primary financing that could sustain or accelerate pricing momentum before year-end. Trader consensus prices these probabilities according to skin-in-the-game capital allocation across private-market platforms.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว




ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย